Brokers Offer Predictions for SABS FY2024 Earnings

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Analysts at Brookline Capital Management dropped their FY2024 EPS estimates for SAB Biotherapeutics in a research report issued to clients and investors on Thursday, November 7th. Brookline Capital Management analyst K. Raja now forecasts that the company will post earnings per share of ($3.58) for the year, down from their prior estimate of ($3.48). The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($3.64) per share. Brookline Capital Management also issued estimates for SAB Biotherapeutics’ Q4 2024 earnings at ($1.12) EPS, FY2025 earnings at ($0.97) EPS, FY2026 earnings at ($0.99) EPS, FY2027 earnings at ($1.02) EPS and FY2028 earnings at ($0.95) EPS.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.12) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.05). SAB Biotherapeutics had a negative return on equity of 94.37% and a negative net margin of 1,450.14%.

Several other equities research analysts also recently commented on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $25.00 target price on shares of SAB Biotherapeutics in a research note on Thursday, November 7th. Craig Hallum initiated coverage on SAB Biotherapeutics in a report on Wednesday, October 9th. They set a “buy” rating and a $11.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of SAB Biotherapeutics in a research note on Monday, August 12th. Finally, Oppenheimer reiterated an “outperform” rating and set a $12.00 price objective on shares of SAB Biotherapeutics in a report on Thursday, September 12th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $12.40.

SAB Biotherapeutics Stock Down 9.1 %

SAB Biotherapeutics stock opened at $3.19 on Monday. The business has a 50-day moving average of $2.90 and a 200-day moving average of $2.99. The company has a debt-to-equity ratio of 0.09, a quick ratio of 5.24 and a current ratio of 3.69. SAB Biotherapeutics has a 1 year low of $2.16 and a 1 year high of $9.72.

Hedge Funds Weigh In On SAB Biotherapeutics

A hedge fund recently bought a new stake in SAB Biotherapeutics stock. First PREMIER Bank acquired a new position in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 19,386 shares of the company’s stock, valued at approximately $60,000. First PREMIER Bank owned approximately 0.21% of SAB Biotherapeutics as of its most recent filing with the Securities & Exchange Commission. 7.82% of the stock is owned by institutional investors and hedge funds.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.